Home Uncategorized Five fallen biotech stocks, we expect rebounds

Five fallen biotech stocks, we expect rebounds


Image source: Hongchum / Pixabay

In 2022, investors in biotechnology tended to be at the wrong end of trade with low absolute performance and relative performance lagging behind the market.

The Nasdaq Biotechnology Index has fallen 19.2% since the beginning of the year compared to a decrease of 18.7% for the Nasdaq Composite and a 10.6% loss for the S&P 500 Index.

With megacap technology stocks leading the market in both directions, we believe that investors who are willing to spend time to do a little research can find opportunities in biotechnology and life sciences, especially in a smaller part of the market capitalization spectrum.

Today, we highlight five that await potential selections over the next 12 months:

Congenital pharmacy

Subscribe to have our Daily Fix delivered to your inbox 5 days a week


BioXcel Therapeutics ( BTAI)

Medicine Editas ( EDIT)

Affiliated ( AFMD)

Genfit ( GNFT)

Which companies do you follow, biotech or others? Let us know and we promise to write about some of the filing. Please email us at editor@equities.com.

Thank you.


Source: Stock news

Share price data is provided by IEX Cloud with a 15-minute delay. Chart cost data is provided by TradingView with a 15-minute delay.

This article is first published on Source link

Previous articlePressure relies on school systems to rebuild classes by pitting politicians against teachers
Next articleGardens of Eden – New World Report